Needham & Company
-
Needham & Company Maintians a 'Hold' on Forest Laboratories (FRX); Q1 Review; Reviewing FDA Calendar
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Continued Growth Challenges, But There Is A Success Factor
-
Needham & Company Maintains a 'Hold' on Forest Labs (FRX); FDA Overwhelmingly Backs Approval of Aclidinium
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Strength of Established Products Drives EPS Beat as New Launches Begin Gaining Traction
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Modest Launch Performance, Increased OpEx Combine to Reveal Softness & Rare EPS Miss
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Solid Q4 Earnings Take Back Seat as Floor Set for Post-Cliff 2013 EPS Performance
-
Notable Analyst Rating Changes 02/23: (AMAT) (AKS) (YOKU) (HOC) Upgraded; (NFLX) (FRX) (MDT) (MRO) Downgraded
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Clinical Data Deal Brings Solid SSRI Entrant Viibryd Though “Too Little Too Late” & Undifferentiated Profile Concerns
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); No Halloween Surprise; FDA Approves Teflaro
-
Needham & Company maintains a 'Hold' on Forest Labs (FRX); Ceftaroline Panel Is A Blow-Out As AdCom Votes To Approve in Both cSSSI & CABP Indications
-
Notable Analyst Rating Changes 07/01: DELL, FDX, LOW, UPS, HD Upgraded; AMED, STP, LGF, HES Downgraded
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Another Shot on Goal Goes Wide; Radipodril Fails to Meet Endpoint
-
Unusual 11 Mid-Day Movers 4/8: RPC, STRM, PGTI, ACMR, CMT Higher; CML, ZEP, FBP, RZ Lower
-
Morning Movers 4/8: RPC, STRM, TCM, CMT, ACMR, HOTT Higher; CML, ZEP, APOG, SCSC, FRX Lower
-
Notable Analyst Rating Changes 12/17: NWSA, UNM, LNC, PTV Upgraded; ADP, AEM, FGXI, OC Downgrades
-
Needham & Co Downgrades Forest Labs (FRX) to Hold
-
Needham & Co Initiates Coverage on Forest Labs (FRX) with a Buy

